|
25 Oct 2021 |
Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors
|
|
25 Oct 2021 |
Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age
|
|
21 Oct 2021 |
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
|
|
21 Oct 2021 |
Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
|
|
21 Oct 2021 |
Daiichi Sankyo Announces Development Progress of mRNA COVID-19 Vaccine in Japan
|
|
21 Oct 2021 |
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
|
|
20 Oct 2021 |
COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy
|
|
18 Oct 2021 |
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
|
|
16 Oct 2021 |
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
|
|
13 Oct 2021 |
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
|
|
13 Oct 2021 |
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
|
|
13 Oct 2021 |
First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Bladder Cancer Sub-Study
|
|
13 Oct 2021 |
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
|
|
07 Oct 2021 |
Imophoron raises GBP 4 million funding for rapid vaccine development
|
|
07 Oct 2021 |
GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine
|
|
06 Oct 2021 |
Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial
|
|
06 Oct 2021 |
Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older
|
|
05 Oct 2021 |
Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine
|
|
04 Oct 2021 |
Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union
|
|
04 Oct 2021 |
Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection Against Lower Respiratory Infections in Older Adults
|
|
01 Oct 2021 |
BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients
|
|
28 Sep 2021 |
Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate
|
|
28 Sep 2021 |
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
|
|
27 Sep 2021 |
CyanVac and Blue Lake Biotechnology Announce First Participant Dosed in a Phase 1 Clinical Trial to Evaluate its CVXGA1 Intranasal COVID-19 Vaccine
|
|
23 Sep 2021 |
Elicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
|
